SCHEDULE: Adage Capital Reduces Aclaris Therapeutics Stake Below 5%
Schedule 13G Amendment
Adage Capital Management and its principals have reported reducing their beneficial ownership in Aclaris Therapeutics, Inc. to 4.87%.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported beneficial ownership of 5,278,144 shares of Aclaris Therapeutics, Inc. common stock.
- This represents 4.87% of the company's outstanding common stock.
- The percentage is calculated based on 108,332,218 shares outstanding as of July 31, 2025, as reported in the company's Quarterly Report on Form 10-Q.
- The filing indicates that the reporting persons no longer hold 5% or more of the class of securities, triggering this Schedule 13G Amendment.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as a significant institutional investor has reduced its stake below the 5% threshold, which could be perceived as a decrease in confidence or a rebalancing decision. However, it's a passive filing and doesn't indicate active opposition or a strong negative view.
Negatives
- A significant institutional investor, Adage Capital Management, has reduced its stake in Aclaris Therapeutics, Inc. to below the 5% reporting threshold, which could be interpreted by some investors as a decrease in conviction or a portfolio rebalancing decision.
Risks
- The reduction in beneficial ownership by a major institutional investor could signal a potential lack of confidence in the company's future prospects or a shift in investment strategy by Adage Capital Management.
Future Outlook
NA
Industry Context
This filing reflects a portfolio adjustment by a large investment firm in the biotechnology/pharmaceutical sector, where Aclaris Therapeutics operates. Such adjustments are common and can be driven by various factors, including company-specific performance, broader market trends, or changes in the fund's investment strategy.
Stakeholder Impact
- Shareholders may interpret the reduction in stake by a major institutional investor as a signal of reduced confidence, potentially influencing their own investment decisions.
Key Dates
| Date | Description |
|---|---|
| 2025-07-31 | Date as of which 108,332,218 shares of Common Stock were outstanding, as reported in the Company's Quarterly Report on Form 10-Q. |
| 2025-08-07 | Date Aclaris Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 2025-09-30 | Date of event which required the filing of this statement (beneficial ownership dropped below 5%). |
| 2025-11-13 | Date the Schedule 13G Amendment No. 2 was signed by the Reporting Persons. |
Keywords
Aclaris Therapeutics, Adage Capital Management, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.